R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Jul 1, 2013 → Jul 1, 2014

NCT ID

NCT01900249

About R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo

R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo is a phase 2 stage product being developed by Rigel Pharmaceuticals for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT01900249. Target conditions include Keratoconjunctivitis Sicca.

What happened to similar drugs?

1 of 9 similar drugs in Keratoconjunctivitis Sicca were approved

Approved (1) Terminated (0) Active (8)

✅Cyclosporine A + DexamethasoneNovartisApproved

🔄FK506Astellas PharmaPhase 3

🔄FK506 + placeboAstellas PharmaPhase 3

🔄OTX-101 0.09%Sun PharmaceuticalPhase 3

🔄cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3

🔄INS365 Ophthalmic SolutionMerckPhase 3

🔄RebamipideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01900249	Phase 2	Completed	Jul 1, 2013	Jul 1, 2014	Keratoconjunctivitis Sicca
NCT01733992	Phase 1	Completed	Nov 1, 2012	Feb 1, 2013	Keratoconjunctivitis Sicca

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	40
FK506 + placebo	Astellas Pharma	Phase 3	40
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	40
OTX-101 0.05% + OTX-101 0.09% + Vehicle	Sun Pharmaceutical	Phase 2/3	38
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	40
INS365 Ophthalmic Solution	Merck	Phase 3	40
Pimecrolimus + Vehicle	Novartis	Phase 2	35
Cyclosporine A + Dexamethasone	Novartis	Approved	43
Rebamipide	Novartis	Phase 3	40
Rebamipide	Novartis	Phase 3	40
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	27
Dupilumab	Regeneron Pharmaceuticals	Phase 2	31
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	23
CF101	Can Fite Biopharma	Phase 3	30
CF101 + Placebo	Can Fite Biopharma	Phase 2	25